AU2021213421B2 - Treatment of cancer - Google Patents

Treatment of cancer Download PDF

Info

Publication number
AU2021213421B2
AU2021213421B2 AU2021213421A AU2021213421A AU2021213421B2 AU 2021213421 B2 AU2021213421 B2 AU 2021213421B2 AU 2021213421 A AU2021213421 A AU 2021213421A AU 2021213421 A AU2021213421 A AU 2021213421A AU 2021213421 B2 AU2021213421 B2 AU 2021213421B2
Authority
AU
Australia
Prior art keywords
nectin
ser
antibody
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021213421A
Other languages
English (en)
Other versions
AU2021213421A1 (en
Inventor
Manel KRAIEM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74494891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2021213421(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of AU2021213421A1 publication Critical patent/AU2021213421A1/en
Application granted granted Critical
Publication of AU2021213421B2 publication Critical patent/AU2021213421B2/en
Priority to AU2025202617A priority Critical patent/AU2025202617A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021213421A 2020-01-31 2021-01-28 Treatment of cancer Active AU2021213421B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025202617A AU2025202617A1 (en) 2020-01-31 2025-04-14 Treatment of cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062968175P 2020-01-31 2020-01-31
US62/968,175 2020-01-31
PCT/EP2021/051938 WO2021151984A1 (en) 2020-01-31 2021-01-28 Treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025202617A Division AU2025202617A1 (en) 2020-01-31 2025-04-14 Treatment of cancer

Publications (2)

Publication Number Publication Date
AU2021213421A1 AU2021213421A1 (en) 2022-06-23
AU2021213421B2 true AU2021213421B2 (en) 2025-02-06

Family

ID=74494891

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021213421A Active AU2021213421B2 (en) 2020-01-31 2021-01-28 Treatment of cancer
AU2025202617A Pending AU2025202617A1 (en) 2020-01-31 2025-04-14 Treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025202617A Pending AU2025202617A1 (en) 2020-01-31 2025-04-14 Treatment of cancer

Country Status (9)

Country Link
US (1) US12594343B2 (https=)
EP (2) EP4096717B1 (https=)
JP (2) JP7682553B2 (https=)
CN (1) CN114845740A (https=)
AU (2) AU2021213421B2 (https=)
CA (1) CA3160557A1 (https=)
DK (1) DK4096717T3 (https=)
ES (1) ES3014740T3 (https=)
WO (1) WO2021151984A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541637A (ja) * 2020-09-15 2023-10-03 シンアフィックス ビー．ブイ． 抗体－エクサテカンコンジュゲート
MX2023005873A (es) * 2020-11-25 2023-06-05 Innate Pharma Tratamiento del cancer.
KR20240035378A (ko) * 2021-03-31 2024-03-15 이머전스 세라퓨틱스 아게 항-넥틴-4 항체 엑사테칸 접합체
EP4086284A1 (en) * 2021-05-07 2022-11-09 Emergence Therapeutics AG Anti-nectin-4 antibody exatecan conjugates
WO2022262516A1 (zh) * 2021-06-18 2022-12-22 北京海步医药科技有限公司 连接子及其缀合物
IL313805A (en) * 2021-12-28 2024-08-01 Beigene Switzerland Gmbh Drug antibody conjugates
US20250205353A1 (en) * 2022-03-23 2025-06-26 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
JP2025517476A (ja) * 2022-05-25 2025-06-05 イナート・ファルマ・ソシエテ・アノニム ネクチン－４結合剤
EP4285935A1 (en) * 2022-06-03 2023-12-06 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
US20230408497A1 (en) * 2022-06-20 2023-12-21 Sysmex Corporation Labeled polypeptide, modified polypeptide, production method for these polypeptides, reagent containing these polypeptides, and measurement method for target substance
WO2024012536A1 (zh) * 2022-07-14 2024-01-18 百奥泰生物制药股份有限公司 抗Nectin-4抗体、其抗体药物偶联物及应用
WO2024012541A1 (zh) * 2022-07-14 2024-01-18 百奥泰生物制药股份有限公司 抗Nectin-4抗体药物偶联物及应用
EP4309676A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
US12576154B2 (en) * 2022-08-01 2026-03-17 Philochem Ag Conjugates of PSMA-binding moieties with cytotoxic agents
EP4324849A1 (en) * 2022-08-18 2024-02-21 Emergence Therapeutics AG Humanized anti-nectin-4 antibodies
EP4344707A1 (en) * 2022-09-29 2024-04-03 Emergence Therapeutics AG New anti-nectin-4 antibody drug conjugates
WO2024078449A1 (en) * 2022-10-09 2024-04-18 LaNova Medicines Limited Compounds, compositions and methods
WO2024091437A1 (en) * 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
WO2024098066A1 (en) * 2022-11-04 2024-05-10 ALX Oncology Inc. Exatecan derivatives and antibody-drug conjugates thereof
JP2025537278A (ja) * 2022-11-09 2025-11-14 オービーアイ ファーマ，インコーポレイテッド 抗体－薬物コンジュゲートの工学のためのグリコシンターゼのバリアント
WO2024191598A1 (en) * 2023-03-10 2024-09-19 Emory University Labeled amplifier oligonucleotides for detecting low or ultra low expression of cancer markers and uses in managing cancer treatments
CN118666946A (zh) * 2023-03-15 2024-09-20 上海亲合力生物医药科技股份有限公司 连接子及使用其的偶联药物、抗体偶联药物及其应用
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
AU2024304180A1 (en) * 2023-06-13 2026-01-08 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
JP7689606B2 (ja) * 2023-06-20 2025-06-06 イーライ リリー アンド カンパニー ネクチン－４抗体及び抗体－薬物コンジュゲート
EP4735047A1 (en) * 2023-06-28 2026-05-06 Université de Tours Pegylated linkers and uses thereof
TW202530249A (zh) 2023-09-29 2025-08-01 美商雅克提斯腫瘤學公司 小蛋白、結合物及其用途
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
EP4534102A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
WO2025078881A2 (en) * 2023-10-13 2025-04-17 Ligachem Biosciences Inc. Anti-claudin 18.2 antibody drug conjugates comprising topoisomerase i inhibitor and uses thereof
US20250121084A1 (en) * 2023-10-17 2025-04-17 Adc Therapeutics Sa Anti-claudin-6 conjugates
FR3155708A1 (fr) * 2023-11-27 2025-05-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
FR3155709A1 (fr) * 2023-11-27 2025-05-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
US20250186604A1 (en) * 2023-12-06 2025-06-12 Adc Therapeutics Sa Anti-psma antibody conjugates
WO2025153092A1 (en) * 2024-01-18 2025-07-24 Beijing Joinn Biologics Co., Ltd Antibody-drug conjugate
WO2025209545A1 (zh) * 2024-04-03 2025-10-09 上海药明合联生物技术有限公司 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物
FR3164899A1 (fr) * 2024-07-24 2026-01-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
EP4732850A1 (en) * 2024-10-25 2026-04-29 Antelope Therapeutics SAS Antibody-drug conjugates and their uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3546448A1 (en) * 2016-11-25 2019-10-02 Mabwell (Shanghai) Bioscience Co., Ltd. Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
EA003398B1 (ru) 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
JP4638225B2 (ja) 2002-05-30 2011-02-23 ザ スクリプス リサーチ インスティテュート 銅を触媒とするアジドとアセチレンのライゲーション
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7807619B2 (en) 2004-11-01 2010-10-05 The Regents Of The University Of California Compositions and methods for modification of biomolecules
EP2222341B1 (en) 2007-11-21 2015-02-25 University Of Georgia Research Foundation, Inc. Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds
US20110301056A1 (en) 2008-12-12 2011-12-08 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
WO2011121453A2 (en) 2010-03-30 2011-10-06 Clavis Pharma Asa Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
MX347954B (es) * 2010-09-29 2017-05-19 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
EP2793947B1 (en) 2011-12-23 2021-02-03 Innate Pharma Enzymatic conjugation of polypeptides
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
CN107106701B (zh) 2014-10-03 2020-11-06 西纳福克斯股份有限公司 磺酰胺接头、其缀合物及制备方法
EP3218009B1 (en) 2014-10-14 2021-04-07 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
EP3347048B1 (en) 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
WO2018226578A1 (en) 2017-06-05 2018-12-13 Agensys, Inc. Nectin-4-binding proteins and methods of use thereof
KR20260011205A (ko) 2017-10-05 2026-01-22 소니그룹주식회사 프로그램가능한 중합체성 약물
JP7381478B2 (ja) 2017-10-23 2023-11-15 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド－薬物－複合体
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CA3114474A1 (en) 2018-09-30 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
CA3128571A1 (en) 2019-03-19 2020-09-24 Paul Scherrer Institut Transglutaminase conjugation method with a glycine based linker
SG11202110922QA (en) * 2019-04-26 2021-10-28 Immunogen Inc Camptothecin derivatives
CA3085001C (en) 2019-05-20 2021-10-05 Mabplex International, Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
US12398206B2 (en) 2019-10-07 2025-08-26 Université D'aixmarseille Antibodies having specificity for nectin-4 and uses thereof
KR20220106779A (ko) 2019-11-25 2022-07-29 어젠시스 인코포레이티드 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)를 사용한 암의 치료
CN113527486B (zh) 2020-04-21 2025-12-02 迈威(上海)生物科技股份有限公司 一种抗Nectin-4的抗体及其应用
CN115768798A (zh) 2020-06-18 2023-03-07 生物蛋白有限公司 条件活性抗粘附分子-4(nectin-4)抗体
EP4208259A2 (en) 2020-09-04 2023-07-12 NovaRock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
JP2023541637A (ja) 2020-09-15 2023-10-03 シンアフィックス ビー．ブイ． 抗体－エクサテカンコンジュゲート
MX2023005873A (es) 2020-11-25 2023-06-05 Innate Pharma Tratamiento del cancer.
JP2025517476A (ja) 2022-05-25 2025-06-05 イナート・ファルマ・ソシエテ・アノニム ネクチン－４結合剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3546448A1 (en) * 2016-11-25 2019-10-02 Mabwell (Shanghai) Bioscience Co., Ltd. Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHALLITA-EID P.M. ET AL: "Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models", CANCER RESEARCH, vol. 76, no. 10, 15 May 2016, pages 3003 - 3013 *

Also Published As

Publication number Publication date
US12594343B2 (en) 2026-04-07
AU2021213421A1 (en) 2022-06-23
CN114845740A (zh) 2022-08-02
JP7682553B2 (ja) 2025-05-26
JP2023512036A (ja) 2023-03-23
EP4512478A3 (en) 2025-05-21
US20230099149A1 (en) 2023-03-30
DK4096717T3 (da) 2025-03-03
EP4512478A2 (en) 2025-02-26
WO2021151984A1 (en) 2021-08-05
EP4096717B1 (en) 2024-12-11
EP4096717A1 (en) 2022-12-07
ES3014740T3 (en) 2025-04-24
AU2025202617A1 (en) 2025-05-15
JP2025121970A (ja) 2025-08-20
CA3160557A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
AU2021213421B2 (en) Treatment of cancer
US12365731B2 (en) NKp46 binding agents
TWI583394B (zh) 抗-ｇｃｃ抗體分子及其相關之組合物及方法
US20240325557A1 (en) Treatment of cancer
CN111212853A (zh) 可活化的抗cd166抗体及其使用方法
KR20250017209A (ko) 넥틴-4 결합제
RU2750817C1 (ru) Применение конъюгата анти-her2 антитело-лекарственное средство при лечении уротелиальной карциномы
CN116685342A (zh) 癌症的治疗

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)